Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Engerix-B® and Fendrix® in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccination and Are Not Seroprotected

NCT01195246 is registered in ClinicalTrials.gov with Dynavax Technologies Corporation as lead sponsor.

NCT NCT01195246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01195246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Engerix-B® and Fendrix® in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccination and Are Not Seroprotected
Lead sponsor
Dynavax Technologies Corporation
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
August 31, 2012
Enrollment
155 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease